SET and MYND domain-containing protein (SMYD) family with methyltransferase activity is involved in cancer progression. This novel meta-analysis aimed to evaluate the association of SMYD family with the clinical and survival outcomes in solid cancer patients.
Razmi, M., Yazdanpanah, A., Etemad-Moghadam, S., Alaeddini, M., Angelini, S., Eini, L. (2022). Clinical prognostic value of the SMYD2/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, NA, 1-15 [10.1080/14737159.2022.2144235].
Clinical prognostic value of the SMYD2/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis
Angelini, Sabrina;
2022
Abstract
SET and MYND domain-containing protein (SMYD) family with methyltransferase activity is involved in cancer progression. This novel meta-analysis aimed to evaluate the association of SMYD family with the clinical and survival outcomes in solid cancer patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Razmi et al., final manuscript vs2 (1).docx
Open Access dal 18/11/2023
Tipo:
Postprint
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
3.07 MB
Formato
Microsoft Word XML
|
3.07 MB | Microsoft Word XML | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
